ReviewOncoTargets and therapy2019
Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy.
Review in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 71 citations in OpenAlex.
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).Oncology reports · 2026Review
- The pre-metastatic niche: mechanisms, heterogeneity, and therapeutic opportunities.Molecular cancer · 2026Review
- Review
- Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment.Communications biology · 2025Review
- Synergistic Antitumor Immunotherapy via Mitochondria Regulation in Macrophages and Tumor Cells by an Iridium Photosensitizer.ACS central science · 2025Article
- Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.Frontiers in chemistry · 2025Review
- Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in BioengineeredACS applied bio materials · 2024Article
- Biomaterial-Based In Situ Cancer Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Circulating tumor cells: from new biological insights to clinical practice.Signal transduction and targeted therapy · 2024Review
- Role of adhesion molecules in cancer and targeted therapy.Science China. Life sciences · 2024Review
- Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies.Cancer research communications · 2024Article
- Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises.Cells · 2024Review
- Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.Journal of biomedical science · 2024Review
- Circulating tumor cells in pancreatic cancer: more than liquid biopsy.Therapeutic advances in medical oncology · 2024Review
- Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools.International journal of nanomedicine · 2024Review
- CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Tumor-derived systems as novel biomedical tools-turning the enemy into an ally.Biomaterials research · 2023Review
- Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy.Biomedicines · 2023Review
- "Bioinspired" Membrane-Coated Nanosystems in Cancer Theranostics: A Comprehensive Review.Pharmaceutics · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of cancer immunotherapy on recognition checkpoints for killing cancer cells has raised a great interest of scientists in understanding new and old methods of immunotherapeutic. CD47 (cluster of differentiation 47) is a cell surface glycoprotein and widely expressed on cells, which belongs to the immunoglobulin (Ig) superfamily as a cell membrane receptor which serves in immune therapy. CD47 is an inhibitory receptor expressed on tumor cell surface and interacts with signal receptor protein-alpha (SIPR-α, also named CD172a or SHPS-1) which may escape from immune cells such as macrophage and T cells. Meanwhile, tumor cells express high CD47 protein which may secrete exosomes with high CD47 expression. The high CD47 expression-exosomes could serve the tumor metastasis process and provide transfer convenience for tumors on the microenvironment. CD47 on cancer cells can also affect the migration and invasion of cells. The high CD47 expression on tumor or CTC (circulating tumor cell) surface means the stronger migration and invasion and makes them escape from immune cells for phagocytosis such as T cells, NK (natural killer) cells and macrophage, which could be used for diagnosis and prognosis on cancer patients. Meanwhile, targeting CD47 combined with other biomarkers such as EpCAM (epithelial cell adhesion molecule), CD44, etc on cancer surface could be used to isolate CTCs from patients' blood. In terms of treatment, anti-CD47 antibody combined with another antibody such as anti-PD-L1 (programmed death-ligand 1) antibody or drugs such as rituximab, DOX or oxaliplatin also has better therapeutic effects and antitumor function to tumors. Using nanomaterials as an intermediary for CD47-related immune therapy could greatly increase the therapeutic effect and overcome multiple biological barriers for anti-CD47 antibody in vivo. In this review, we discuss the important role and the function of CD47 in tumor metastasis and also provide a reference for related research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.